MetaVia (MTVA) Income from Continuing Operations (2015 - 2026)
MetaVia's (MTVA) quarterly Income from Continuing Operations came in at 1930000.0 in Q4 2025, up 62.69% YoY from 1186298.72 in Q4 2024, and up 42.85% on a QoQ basis from 3377000.0 in Q3 2025.
MetaVia (MTVA) Income from Continuing Operations (2015 - 2026) Analysis & Trends
MetaVia (MTVA) has 11 years of Income from Continuing Operations data on file, last reported at 1930000.0 in Q4 2025.
- Quarterly Income from Continuing Operations rose 62.69% year-over-year to 1930000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 12973000.0 (up 52.98% YoY) and the FY2025 annual result came in at 12973000.0, up 52.98% from the prior year.
- Income from Continuing Operations rose to 1930000.0 in Q4 2025, from 3377000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 7154000.0 in Q4 2023 to a low of 10053000.0 in Q2 2024.
- A 5-year average of 3520500.0 and a median of 3566000.0 in 2021 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations surged 235.8% — and 2024, when it sank 1269.62%.
- Tracing MTVA's Income from Continuing Operations over 5 years: stood at 4578000.0 in 2021, then decreased by 15.07% to 5268000.0 in 2022, then surged by 235.8% to 7154000.0 in 2023, then tumbled by 172.31% to 5173000.0 in 2024, then soared by 62.69% to 1930000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 1930000.0 (Q4 2025), 3377000.0 (Q3 2025), and 3995000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | -5.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.32 Mn |
| Dec 31, 2025 | -1.93 Mn |
| Sep 30, 2025 | -3.38 Mn |
| Jun 30, 2025 | -4.00 Mn |
| Mar 31, 2025 | -3.67 Mn |
| Dec 31, 2024 | -5.17 Mn |
| Sep 30, 2024 | -5.65 Mn |
| Jun 30, 2024 | -10.05 Mn |
| Mar 31, 2024 | -6.71 Mn |
| Dec 31, 2023 | 7.15 Mn |
| Sep 30, 2023 | -3.82 Mn |
| Jun 30, 2023 | -734,000.00 |
| Mar 31, 2023 | -2.60 Mn |
| Dec 31, 2022 | -5.27 Mn |
| Sep 30, 2022 | -3.11 Mn |
| Jun 30, 2022 | -3.30 Mn |
| Mar 31, 2022 | -2.88 Mn |
| Dec 31, 2021 | -4.58 Mn |
| Sep 30, 2021 | -3.46 Mn |
| Jun 30, 2021 | -3.92 Mn |